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oxybutinin treatment and were switched to TER. HRQoL data
were collected through the symptom bother subscale of the
OAB-q questionnaire which was administered at three different
time points: before (M0) and after 3 (M3) and 12 Months or
more (M12) of TER treatment. Efﬁcacy and tolerability of TER
treatment were also investigated. RESULTS: A total of 168
patient questionnaires of M3 and 93 of M12 were compared to
baseline questionnaires (M0). The average age (SD) was 59
(16.9), patients were mainly female (70%). The mean total
score (SD) of the OAB-q subscale decreased from 29.13
(9.12) to 18.16 (7.53) at M3 and to 17.14 (7.01) at M12
(p < 0.001) compared to baseline oxybutinin treatment, exceed-
ing the “Minimally Important Difference” of 10 points. All indi-
vidual OAB-q symptom bother items showed an improvement
with the highest impact on micturition frequency (27% at M3,
30% at M12) and uncomfortable/sudden urge to urinate (28% at
M3, 30% at M12) (p < 0.001). The % of patients reporting
improvement in the treatment related adverse events such as
memory, vertigo, constipation and dry mouth further increased
from M3 to M12 compared to baseline oxybutinin treatment,
with the most pronounced improvement for dry mouth: 58% at
M3, 61% at M12 (p < 0.001). CONCLUSION: The data pre-
sented in this real life study show that TER improved the Health
Related Quality of Life of patients with a neurogenic OAB. Based
upon these results the reimbursement of TER was maintained in
Belgium.
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OBJECTIVES: Renal replacement therapy gives rise to range of
beliefs and problems. In order to make sense of and respond to
the illness, patients create their own representations of their
illness. These can including doubts or false beliefs about the
illness, treatment beneﬁts, and compliance. Different representa-
tions have different effects on clinical outcomes, since they are
modulating the relationship between the patient and the illness-
.The aims of this study were, 1) to explore the illness represen-
tations and the relationship with the Health Related Quality of
Life (HRQoL), anxiety and depression; 2) to identify patient
characteristics and factors can inﬂuence them. METHODS: This
is a cross-sectional study with 200 randomized transplant recipi-
ents with different time since transplant. Illness representations
were evaluated using The Revised Illness Perception Question-
naire, the HRQoL using the SF-36 Health Survey and patients
also answered Hospital Anxiety and Depression scale (HADS). A
comorbidity index, sociodemographic and clinical data were also
collected. RESULTS: There are previous results of the ﬁrst 30
patients with at least six months since transplant and the
maximum eighteen months. Higher hospital admissions, higher
comorbidity, and lower hemoglobin and haematocrit levels have
negative inﬂuence on their representations (p < 0.05). On the
other hand illness representations were correlated with the
mental aspects of the HRQoL (p < 0.05), but not with the physi-
cal. To have hereditary renal disease, not to assume the illness as
a chronic, to report higher negative consequences in the diary life
by it, and to perceive lower personal control about the illness,
were correlated with higher anxiety and depression(p < 0.05).
CONCLUSION: Patients’ beliefs are likely to have an important
impact on their adjustment to their illness.To identify those
patients with false or negative beliefs is necessary in order to
avoid lower HRQoL, anxiety, depression, and behaviours such as
noncompliance with immunosuppressants, major cause of renal
transplant failure in younger people.
POSTER SESSION II
HEALTH CARE DECISIONS USING OUTCOMES
RESEARCH CASE STUDIES
CASE1
UTILIZING AN INTERNET-BASED SYSTEMTO DELIVER A
PHARMACY-CENTRIC ALERT AND INTERVENTION IN
A MANAGED CARE SETTING
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ORGANIZATION: Medicare Advantage–Prescription Drug
Program Provider. PROBLEM OR ISSUE ADDRESSED: Medi-
care beneﬁciaries with Part-D coverage were consistently reach-
ing their gap in coverage early in the plan year resulting in poor
medication adherence, persistence and treatment outcomes.
GOALS: The organization hoped to improve the cost-
effectiveness of the drug selection choices made by the member
and physician. The organization encouraged its members to
utilize lower cost generic medications to help lower costs and
avoid their coverage gap. OUTCOMES ITEMS USED IN THE
DECISION: Adherence and persistence data and evidence from
other pharmacy-based programs extracted from the literature
was used to determine that the main outcome measure objectives
were to be improved generic utilization, no decrease in essential
maintenance medications, and decreased gross costs per member
per month. IMPLEMENTATION STRATEGY: An internet-
based pharmacy therapy quality assurance system was built to
identify members that were expected to reach their coverage gap
within the plan year. The members’ proﬁles were reviewed by the
staff pharmacist for lower cost therapeutic alternative generic
medications. The members were sent a letter (and possibly their
physician) about available drug alternatives. RESULTS: •16.3%
increased generic utilization vs. 6.8% increase in control group
•2.9% decreased essential medication PMPM vs. 3.8% decrease
in control group •4.5% decrease in gross cost PMPM vs. 5.0%
increase in control group LESSONS LEARNED: That a
pharmacist-driven, internet-based intervention can improve cost-
effective drug therapy. However, the amount of efﬁcient spending
is dependent upon the efﬁciency in which the program is
delivered. Greater efﬁciencies will need to be considered for
broader population exposure.
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ORGANIZATION: The Pharmaceutical Beneﬁts Board in
Sweden (LFN) PROBLEM OR ISSUE ADDRESSED: The LFN is
in the process of reviewing the reimbursement status of all phar-
maceuticals. The reviews are done by therapeutic area (based
primarily on ATC3-codes). This is done in order to ensure that all
products used are cost-effective and fulﬁLl the criteria for reim-
bursement. GOALS: To assess the cost-effectiveness of the drugs
used to treat asthma and COPD and to reach a decision on the
continued reimbursement status of these products. The inhaled
medications used for treating asthma and COPD (steroids, beta-
agonists and combinations) are a major part of this therapeutic
area. OUTCOMES ITEMS USED IN THE DECISION: The
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